Immunodiagnostic Systems Announcements

Trading Statement

13 October 2008 07:00:08



RNS Number : 6411F Immunodiagnostic Systems Hldgs PLC 13 October 2008  
?
    

Immunodiagnostic Systems Holdings plc

Pre - Close Trading Update 

Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of diagnostic testing kits for the clinical and research markets, is pleased to announce that turnover for the first six months of this year is in line with management expectations. Sales are up 84.5% compared to the same period last year and on a pro-forma basis the comparative is 21%. The continued growth in the business reflects the increasing clinical recognition of the value of Vitamin D not only as a marker of bone disease but also its value as a marker of general well-being.

The development of assays for the IDSiSYS, previously referred to as the 3x3, continues apace and we anticipate the first commercial shipments of both the IDSiSYS instrument and the Company's flagship Vitamin D product to commence in January 2009. 

Discussions with regard to the disposal of the Company's haematology business continue to advance and the market will be updated when appropriate.

Trading continues to be in line with expectations and the Board remains confident for the financial year as a whole to 31 March 2009.

IDS will announce Interim Results for the six months ended 30 September 2008 during December 2008. 
 For further information:

Immunodiagnostic Systems Holdings plc
Tel: 0191 519 0660
Roger Duggan, Chief Executive Officer  

Paul Hailes, Finance Director

Oriel Securities Limited 
Tel: 020 7710 7600
(Nominated Adviser and Broker)

Andrew Edwards, Gareth Price, James Nevin  

Parkgreen Communications Limited     
Tel: 020 7933 8787
Paul McManus
Mob: 07980 541 893

paul.mcmanus@parkgreenmedia.com
Ben Knowles
Mob: 07900 346 978

Ben.knowles@parkgreenmedia.com

            

    

            
                
              
   
This information is provided by RNSThe company news service from the London Stock Exchange  END  TSTGGMMGVGVGRZM

All data suppied by Digital Look (15 minute delay)




Risk Warning

There is an extra risk of losing money when shares are bought in some smaller companies including 'Penny Shares'. There is a big difference between the buying price and the selling price of these shares. If they have to be sold immediately, you may get back much less than you paid for them or you may have difficulty in selling them. Past performance is not a reliable indicator of future results. The price may change quickly and it may go down as well as up. You could lose every penny put into a particular share.

The information contained above has been compiled from documented sources which are believed to be reliable but, due to their very nature, are subject to a degree of historical inaccuracy and have not been independently verified and cannot be guaranteed. The pages on this website are provided for information only. City Equities Limited will not accept responsibility for loss incurred by any person or body acting, or refraining from acting, as a result of information and/or opinions given anywhere on this website. Issued by City Equities Limited, Aldermary House, 10-15 Queen Street, London, EC4N 1TY. Registered in England. Registered No. 2742847. Registered Address: Amwell House, 19 Amwell Street, Hoddeson, Herts. EN11 8TS. City Equities Limited is Authorised and regulated by the Financial Services Authority. Registration No. 155051.